Clovis Oncology Inc. (CLVS)

17.14
0.79 4.80
NASDAQ : Health Technology
Prev Close 16.36
Open 16.71
Day Low/High 16.63 / 17.61
52 Wk Low/High 11.50 / 51.76
Volume 671.17K
Avg Volume 1.62M
Exchange NASDAQ
Shares Outstanding 53.01M
Market Cap 904.80M
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Oncology Announces Presentations At 2019 ASCO Annual Meeting

Clovis Oncology Announces Presentations At 2019 ASCO Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that four abstracts featuring data for Rubraca ® (rucaparib) and ongoing studies in multiple tumor types will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking...

Clovis Oncology Announces First Quarter 2019 Operating Results

Clovis Oncology Announces First Quarter 2019 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended March 31, 2019, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the rest of the year.

Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2019

Clovis Oncology To Present At The Bank Of America Merrill Lynch Healthcare Conference 2019

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Enters Into Non-Dilutive Clinical Trial Financing With TPG Sixth Street Partners For Up To $175 Million

Clovis Oncology Enters Into Non-Dilutive Clinical Trial Financing With TPG Sixth Street Partners For Up To $175 Million

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that it has entered into an agreement for up to $175 million in non-dilutive clinical trial financing with certain affiliates of TPG Sixth Street Partners to reimburse Clovis' costs and expenses related...

Clovis Oncology To Announce First Quarter 2019 Financial Results And Host Webcast Conference Call On May 7

Clovis Oncology To Announce First Quarter 2019 Financial Results And Host Webcast Conference Call On May 7

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2019 financial results on Tuesday, May 7, 2019, before the open of the U.

Clovis Oncology Announces Interim Results From Rubraca® (rucaparib) Phase 2 Study In Advanced Pancreatic Cancer And Nonclinical Data In Multiple Solid Tumor Types For Rucaparib And Lucitanib Presented At AACR 2019

Clovis Oncology Announces Interim Results From Rubraca® (rucaparib) Phase 2 Study In Advanced Pancreatic Cancer And Nonclinical Data In Multiple Solid Tumor Types For Rucaparib And Lucitanib Presented At AACR 2019

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced multiple presentations at the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, March 29 - April 3, 2019.

Clovis Oncology Announces Presentations At 2019 AACR Annual Meeting

Clovis Oncology Announces Presentations At 2019 AACR Annual Meeting

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that six abstracts highlighting progress in the Rubraca clinical development and lucitanib preclinical research programs will be presented at the 2019 American Association for Cancer Research (AACR)...

Clovis Oncology To Highlight Rubraca® (rucaparib) Data From Post-Hoc ARIEL3 Analyses At SGO 2019 Congress

Clovis Oncology To Highlight Rubraca® (rucaparib) Data From Post-Hoc ARIEL3 Analyses At SGO 2019 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that data from post hoc exploratory analyses from the ARIEL3 Phase 3 clinical study of Rubraca will be presented during oral plenary and poster sessions at the Society of Gynecologic Oncology 2019...

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology To Present At The Barclays Global Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

ARIEL3 Trial Fact Sheet

ARIEL3 Trial Fact Sheet

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that Rubraca ® (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian...

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

3 Biotech Stocks Boasting Earnings Beats - and Healthy Outlooks

Quick takes on fourth-quarter results from these 3 biotech names.

Clovis Oncology Announces 2018 Operating Results

Clovis Oncology Announces 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter and year ended December 31, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for 2019.

Clovis Oncology To Present At The 8th Annual SVB Leerink Healthcare Conference

Clovis Oncology To Present At The 8th Annual SVB Leerink Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

-- Combinations of ALKS 4230 with Rucaparib and Lucitanib to be Evaluated in Multiple Preclinical Tumor Models --

Clovis Oncology To Announce Fourth Quarter/Fiscal Year 2018 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology To Announce Fourth Quarter/Fiscal Year 2018 Financial Results And Host Webcast Conference Call On February 26

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its fourth quarter/fiscal year 2018 financial results on Tuesday, February 26, 2019, before the open of the U.

Clovis Oncology Announces European Commission Authorization Of Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology Announces European Commission Authorization Of Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Commission (EC) has approved the use of Rubraca ® (rucaparib) for a second indication, as monotherapy for the maintenance treatment of adults with platinum-sensitive relapsed...

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

Dow Pares Gains Into Close as Wall Street Monitors U.S.-China Trade Talks

The Dow Jones Industrial Average is higher Monday amid improved prospects for a trade deal between the U.S. and China.

Clovis Oncology Announces Product Revenues For The Fourth Quarter And Full Year 2018

Clovis Oncology Announces Product Revenues For The Fourth Quarter And Full Year 2018

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced its preliminary, unaudited revenues for the fourth quarter and full year ended December 31, 2018.

First Week Of CLVS February 15th Options Trading

First Week Of CLVS February 15th Options Trading

Investors in Clovis Oncology Inc saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CLVS options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Clovis Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology To Present At The 37th Annual J.P. Morgan Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that its Chief Executive Officer and President, Patrick J.

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

CHMP Grants Positive Opinion For New Indication Of Clovis Oncology's Rubraca®▼ (rucaparib) Tablets As Maintenance Treatment For Women With Relapsed Ovarian Cancer

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union's (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending an additional indication to include...

Clovis Oncology Announces Positive Outcome In European Opposition Proceeding Related To Rubraca®

Clovis Oncology Announces Positive Outcome In European Opposition Proceeding Related To Rubraca®

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153 in amended form covering certain crystalline forms of rucaparib camsylate,...

First Week Of CLVS July 2019 Options Trading

First Week Of CLVS July 2019 Options Trading

Investors in Clovis Oncology Inc saw new options become available this week, for the July 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Clovis Oncology Announces Second U.S. Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Clovis Oncology Announces Second U.S. Patent Issued In Rucaparib High Dosage Strength Tablet Patent Family With Expiration In 2035

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating cancer with high dosage strength rucaparib camsylate formulations.

Clovis Oncology To Present At The Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology To Present At The Credit Suisse 27th Annual Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.

Clovis Oncology Announces Third Quarter 2018 Operating Results

Clovis Oncology Announces Third Quarter 2018 Operating Results

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2018, and provided an update on the Company's clinical development programs and regulatory and commercial outlook for the remainder of 2018.

Clovis Oncology Presents Initial Results From The Ongoing Rubraca® (rucaparib) TRITON Program In Metastatic Castration Resistant Prostate Cancer (mCRPC) At ESMO 2018 Congress

Clovis Oncology Presents Initial Results From The Ongoing Rubraca® (rucaparib) TRITON Program In Metastatic Castration Resistant Prostate Cancer (mCRPC) At ESMO 2018 Congress

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced initial data from its ongoing Phase 2 TRITON2 clinical trial of Rubraca at the ESMO 2018 Congress (European Society for Medical Oncology).

TheStreet Quant Rating: D- (Sell)